Michaela Uloho-Okundaye
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Michaela Uloho-Okundaye has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- David T. Kim
Harvard College, Harvard University, Cambridge, MA 02138, USA
1 shared publication - Min J. Kim
Harvey W. Cushing Neuro-Oncology Laboratories, Department of Neurological Surgery, Mass General Brigham and Harvard Medical School, Boston, MA 02114, USA
1 shared publication - Santosh Guru
School of Clinical Medicine, University of Cambridge, Cambridge CB2 1TN, UK
1 shared publication - Stephen C. Frederico
Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
1 shared publication - Steven D. Chang
Department of Neurosurgery, Stanford University School of Medicine, Stanford, USA
1 shared publication
Latest Publications
- Open Access
- 21 August 2025
- Published by MDPI AG in Brain Sciences
- Vol. 15 (8) , 896
Advancing Medulloblastoma Therapy in Pediatrics: Integrative Molecular Classification and Emerging Treatments
Medulloblastoma (MB), the most common malignant pediatric brain tumor, has undergone reclassification from a histologically defined disease to a genetically stratified spectrum of distinct subgroups: WNT, SHH, Group 3, and Group 4. Advances in molecular profiling, as captured in the 2021 WHO CNS5 classification, have shown meaningful heterogeneity in terms of tumor biology, prognosis, and therapeutic response. However, translating these insights into precise, less toxic treatments remains an ongoing challenge. This review synthesizes current knowledge on MB subgroup biology, treatment strategies, and emerging therapies such as subgroup-specific inhibitors, immunotherapies, and novel chemotherapeutic regimens. This review also explores risk-adapted approaches while addressing global disparities in access to diagnostics and care. As the field moves toward individualized medicine, closing the gap between molecular understanding and equitable implementation will be crucial to improving outcomes and quality of life for children with medulloblastoma worldwide.
- 21 August 2025
- Published by MDPI AG in Brain Sciences
- Vol. 15 (8) , 896
Open AccessAdvancing Medulloblastoma Therapy in Pediatrics: Integrative Molecular Classification and Emerging Treatments
Medulloblastoma (MB), the most common malignant pediatric brain tumor, has undergone reclassification from a histologically defined disease to a genetically stratified spectrum of distinct subgroups: WNT, SHH, Group 3, and Group 4. Advances in molecular profiling, as captured in the 2021 WHO CNS5 classification, have shown meaningful heterogeneity in terms of tumor biology, prognosis, and therapeutic response. However, translating these insights into precise, less toxic treatments remains an ongoing challenge. This review synthesizes current knowledge on MB subgroup biology, treatment strategies, and emerging therapies such as subgroup-specific inhibitors, immunotherapies, and novel chemotherapeutic regimens. This review also explores risk-adapted approaches while addressing global disparities in access to diagnostics and care. As the field moves toward individualized medicine, closing the gap between molecular understanding and equitable implementation will be crucial to improving outcomes and quality of life for children with medulloblastoma worldwide.